C4 Therapeutics Stock Pattern Recognition Three Stars In The South
| CCCC Stock | USD 2.72 -0.03 -1.09% |
| Symbol |
Recognition |
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. The Three Stars In the South pattern shows the slowdown of C4 Therapeutics particular trend.
C4 Therapeutics Technical Analysis Modules
Most technical analysis of C4 Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for CCCC from various momentum indicators to cycle indicators. When you analyze CCCC charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people. A high-level view of C4 Therapeutics emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 1.05, profit margin of -2.92%. C4 Therapeutics has a market cap of 268.34 M, ROE of -44.44%.
Methodology
Unless otherwise specified, financial data for C4 Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. CCCC (USA Stocks:CCCC) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for C4 Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
C4 Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards C4 Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, C4 Therapeutics' short interest history, or implied volatility extrapolated from C4 Therapeutics options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Data Storage Invested few shares | |
 | FinTech Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Social Domain Invested few shares | |
 | Driverless Cars Invested few shares | |
 | Advertising Invested few shares | |
 | Blockchain Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Artificial Intelligence Invested few shares | |
 | Warren Buffett Holdings Invested over 20 shares | |
 | Momentum Invested few shares |
More Resources for CCCC Stock Analysis
A structured review of C4 Therapeutics often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame C4 Therapeutics Stock in context:C4 Therapeutics has a market cap of 268.34 M, operating margin of -2.1%, ROE of -44.44%. Use Trending Equities to explore allocation context. This includes a position in C4 Therapeutics across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy CCCC Stock please use our How to Buy CCCC Stock guide.Analysis related to C4 Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
The market value of C4 Therapeutics is measured differently than book value, which reflects CCCC accounting equity. C4 Therapeutics' market capitalization is 268.34 M. A P/B ratio of 1.05 indicates the market values C4 Therapeutics above its accounting book value. Enterprise value stands at 80.27 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that C4 Therapeutics' intrinsic value and market price are different measures derived from different inputs. For C4 Therapeutics, key inputs include a P/B ratio of 1.05, a profit margin of -2.92%, ROE of -44.44%, and revenue of 35.95 M. Trading price represents the transaction level agreed by market participants.